Skip to content
HowShorted

CRISPR Therapeutics AG short interest in 2020

In 2020, CRISPR Therapeutics AG's disclosed short interest ran from 5.93% of shares outstanding on 15 Jan 2020 to 5.48% on 31 Dec 2020, a change of -0.45 percentage points. The year's high was 8.96% on 30 Oct 2020 and its low 4.70% on 14 Feb 2020, averaging 6.18% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.35 days on 30 Sep 2020. Full history: CRISPR Therapeutics AG.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for CRISPR Therapeutics AG in 2020

2020 in figures

Start of year
5.93% (15 Jan 2020)
End of year
5.48% (31 Dec 2020)
Change
-0.45 pp
High
8.96% (30 Oct 2020)
Low
4.70% (14 Feb 2020)
Average
6.18%
Highest days to cover
10.35 (30 Sep 2020)
SEC filings marked
8

Every report in 2020

CRISPR Therapeutics AG short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 20205.93%3.03
31 Jan 20205.59%3.55
14 Feb 20204.70%2.7010-K filed, results (8-K)
28 Feb 20205.17%2.60
13 Mar 20205.43%3.65
31 Mar 20205.37%3.91
15 Apr 20205.92%4.40
30 Apr 20206.58%5.6610-Q filed, results (8-K)
15 May 20207.00%4.57
29 May 20206.37%3.94
15 Jun 20206.29%5.24
30 Jun 20206.78%4.09
15 Jul 20204.86%1.88
31 Jul 20206.16%5.9810-Q filed, results (8-K)
14 Aug 20206.46%6.30
31 Aug 20206.35%4.70
15 Sep 20206.68%6.31
30 Sep 20206.85%10.35
15 Oct 20207.55%4.50
30 Oct 20208.96%4.7510-Q filed, results (8-K)
13 Nov 20206.64%6.03
30 Nov 20206.09%7.20
15 Dec 20205.10%1.99
31 Dec 20205.48%1.73

See also: CRISPR Therapeutics AG's full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.